Comparison of clinical features and immunological parameters of patients with dehydrating diarrhoea infected with Inaba or Ogawa serotypes of Vibrio cholerae O1

Scandinavian Journal of Infectious Diseases

Volumn 42, Issue 1, 2010, Pages 48-56

  Khan, Ashraful I ^a   Chowdhury, Fahima ^a   Harris, Jason B ^b,c   Larocque, Regina C ^b,c   Faruque, Abu S G ^a   Ryan, Edward T ^b,c   Calderwood, Stephen B ^b,c   Qadri, Firdausi ^a  

^a INTERNATIONAL CENTRE FOR DIARRHOEAL DISEASE RESEARCH   (Bangladesh)

^b MASSACHUSETTS GENERAL HOSPITAL   (United States)

^c HARVARD MEDICAL SCHOOL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AZITHROMYCIN; BACTERIAL ANTIGEN; CHOLERA TOXIN B SUBUNIT; CHOLERA VACCINE; CIPROFLOXACIN; COTRIMOXAZOLE; DOXYCYCLINE; ERYTHROMYCIN; IMMUNOGLOBULIN A ANTIBODY; IMMUNOGLOBULIN G ANTIBODY; LIPOPOLYSACCHARIDE; SULFAMETHOXAZOLE; TETRACYCLINE; TOXIN COREGULATED PILUS SUBUNIT; TRIMETHOPRIM; UNCLASSIFIED DRUG; ANTIINFECTIVE AGENT; BACTERIUM ANTIBODY; CHOLERA TOXIN; IMMUNOGLOBULIN G;

ABDOMINAL PAIN; ADOLESCENT; AGE; ANTIBIOTIC SENSITIVITY; ANTIBODY RESPONSE; ARTICLE; BACTERIAL STRAIN; BANGLADESH; BLOOD SAMPLING; CLINICAL FEATURE; CONTROLLED STUDY; CORRELATION ANALYSIS; DIARRHEA; DISEASE DURATION; FECES ANALYSIS; FEMALE; FLUID THERAPY; HOSPITAL PATIENT; HUMAN; IMMUNE RESPONSE; LYMPHOCYTE; MALE; NONHUMAN; RISK FACTOR; SEROTYPE; VIBRIO CHOLERAE; VOMITING; ADULT; AGED; BLOOD; CHILD; CHOLERA; CLASSIFICATION; COMPARATIVE STUDY; DEHYDRATION; DRUG EFFECT; FECES; IMMUNOLOGY; INFANT; ISOLATION AND PURIFICATION; MICROBIAL VIABILITY; MICROBIOLOGICAL EXAMINATION; MICROBIOLOGY; MIDDLE AGED; PATHOLOGY; PRESCHOOL CHILD; SEROTYPING;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; ANTI-BACTERIAL AGENTS; ANTIBODIES, BACTERIAL; BANGLADESH; CHILD; CHILD, PRESCHOOL; CHOLERA; CHOLERA TOXIN; DEHYDRATION; ERYTHROMYCIN; FECES; FEMALE; HUMANS; IMMUNOGLOBULIN G; INFANT; LIPOPOLYSACCHARIDES; MALE; MICROBIAL SENSITIVITY TESTS; MICROBIAL VIABILITY; MIDDLE AGED; SEROTYPING; TETRACYCLINE; VIBRIO CHOLERAE O1; YOUNG ADULT;

EID: 77149127088     PISSN: 00365548     EISSN: 16511980     Source Type: Journal    
DOI: 10.3109/00365540903289688     Document Type: Article

References (46)

1. Woodward WE, Mosley WH. The spectrum of cholera in rural Bangladesh. II. Comparison of El Tor Ogawa and classical Inaba infection. Am J Epidemiol 1972;96:342-351
2. Reidl J, Klose KE. Vibrio cholerae and cholera: out of the water and into the host. FEMS Microbiol Rev 2002;26: 125-139
3. Koelle K, Pascual M, Yunus M. Pathogen adaptation to seasonal forcing and climate change. Proc Biol Sci 2005;272: 971-977
4. Stroeher UH, Karageorgos LE, Morona R, Manning PA. Serotype conversion in Vibrio cholerae O1. Proc Natl Acad Sci U S A 1992;89:2566-2570
5. Raychoudhuri A, Chatterjee S, Pazhani GP, Nandy RK, Bhattacharya MK, Bhattacharya SK, et al. Molecular characterization of recent Vibrio cholerae O1, El Tor, Inaba strains isolated from hospitalized patients in Kolkata, India. J Infect 2007;55:431-438
6. Hisatsune K, Kondo S, Isshiki Y, Iguchi T, Haishima Y. Occurrence of 2-O-methyl-N-(3-deoxy-L-glycero-tetronyl)- D-perosamine (4-amino-4,6-dideoxy- D-manno-pyranose) in lipopolysaccharide from Ogawa but not from Inaba O forms of O1 Vibrio cholerae. Biochem Biophys Res Commun 1993;190:302-307
7. Ito T, Higuchi T, Hirobe M, Hiramatsu K, Yokota T. Identification of a novel sugar, 4-amino-4,6-dideoxy-2-O-methylmannose in the lipopolysaccharide of Vibrio cholerae O1 serotype Ogawa. Carbohydr Res 1994;256:113-128
8. Wang J, Villeneuve S, Zhang J, Lei P, Miller CE, Lafaye P, et al. On the antigenic determinants of the lipopolysaccharides of Vibrio cholerae O:1, serotypes Ogawa and Inaba. J Biol Chem 1998;273:2777-2783
9. Longini IM Jr, Yunus M, Zaman K, Siddique AK, Sack RB, Nizam A. Epidemic and endemic cholera trends over a 33-year period in Bangladesh. J Infect Dis 2002;186: 246-251
10. Venkatraman KV. A note on the reappearance of the Inaba type of V. cholerae in the Madras province. New Delhi: Indian Research Fund Association; 1947. p 10.
11. Felsenfeld O. A review of recent trends in cholera research and control. With an annex on the isolation and identification of cholera vibrios. Bull World Health Organ 1966;34: 161-195
12. Barua D. History of cholera. In: Barua D, Greenough WB, editors. Cholera. New York: Plenum Press; 1992. pp 1-35.
13. Pollitzer R, Swaroop S, Burrows W. Cholera. Monogr Ser World Health Organ 1959;58:1001-1019
14. Dalsgaard A, Skov MN, Serichantalergs O, Echeverria P, Meza R, Taylor DN. Molecular evolution of Vibrio cholerae O1 strains isolated in Lima, Peru, from 1991 to 1995. J Clin Microbiol 1997;35:1151-1156
15. Bhaskaran K, Gorrill RH. A study of antigenic variation in Vibrio cholerae. J Gen Microbiol 1957;16:721-729
16. Sack RB, Miller CE. Progressive changes of Vibrio serotypes in germ-free mice infected with Vibrio cholerae. J Bacteriol 1969;99:688-695
17. Ryan ET, Calderwood SB, Qadri F. Live attenuated oral cholera vaccines. Expert Rev Vaccines 2006;5:483-494
18. Harris JB, Khan AI, LaRocque RC, Dorer DJ, Chowdhury F, Faruque AS, et al. Blood group, immunity, and risk of infection with Vibrio cholerae in an area of endemicity. Infect Immun 2005;73:7422-7427
19. Asaduzzaman M, Ryan ET, John M, Hang L, Khan AI, Faruque AS, et al. The major subunit of the toxin-coregulated pilus TcpA induces mucosal and systemic immunoglobulin A immune responses in patients with cholera caused by Vibrio cholerae O1 and O139. Infect Immun 2004;72: 4448-4454
20. Chowdhury F, Khan AI, Harris JB, LaRocque RC, Chowdhury MI, Ryan ET, et al. A comparison of clinical and immunologic features in children and older patients hospitalized with severe cholera in Bangladesh. Pediatr Infect Dis J 2008;27:986-992
21. Qadri F, Ryan ET, Faruque AS, Ahmed F, Khan AI, Islam MM, et al. Antigen-specific immunoglobulin A antibodies secreted from circulating B cells are an effective marker for recent local immune responses in patients with cholera: comparison to antibody-secreting cell responses and other immunological markers. Infect Immun 2003;71: 4808-4814
22. Stoll BJ, Glass RI, Huq MI, Khan MU, Holt JE, Banu H. Surveillance of patients attending a diarrhoeal disease hospital in Bangladesh. Br Med J (Clin Res Ed) 1982;285: 1185-1188
23. Begum YA, Talukder KA, Nair GB, Khan SI, Svennerholm AM, Sack RB, et al. Comparison of enterotoxigenic Escherichia coli isolated from surface water and diarrhoeal stool samples in Bangladesh. Can J Microbiol 2007;53:19-26.
24. Faruque AS, Alam K, Malek MA, Khan MG, Ahmed S, Saha D, et al. Emergence of multidrug-resistant strain of Vibrio cholerae O1 in Bangladesh and reversal of their susceptibility to tetracycline after two years. J Health Popul Nutr 2007;25:241-243
25. Saha D, Karim MM, Khan WA, Ahmed S, Salam MA, Bennish ML. Single-dose azithromycin for the treatment of cholera in adults. N Engl J Med 2006;354:2452-2462
26. Woodward WE. Cholera reinfection in man. J Infect Dis 1971;123:61-66
27. Clemens JD, van Loon F, Sack DA, Rao MR, Ahmed F, Chakrabort YJ, et al. Biotype as determinant of natural immunising effect of cholera. Lancet 1991;337:883-884
28. Benenson AS, Mosley WH, Fahimuddin M, Oseasohn RO. Cholera vaccine field trials in east Pakistan. 2. Effectiveness in the field. Bull World Health Organ 1968;38:359-372
29. Manning PA. Surface-associated and soluble components of Vibrio cholerae involved in bacteria-host interactions. Curr Top Microbiol Immunol 1994;192:265-281
30. Koelle K, Pascual M, Yunus M. Serotype cycles in cholera dynamics. Proc Biol Sci 2006;273:2879-2886
31. Merson MH, Martin WT, Craig JP, Morris GK, Blake PA, Craun GF, et al. Cholera on Guam, 1974: epidemiologic findings and isolation of non-toxinogenic strains. Am J Epidemiol 1977;105:349-361
32. Garg P, Nandy RK, Chaudhury P, Chowdhury NR, De K, Ramamurthy T, et al. Emergence of Vibrio cholerae O1 biotype El Tor serotype Inaba from the prevailing O1 Ogawa serotype strains in India. J Clin Microbiol 2000; 38:4249-4253
33. Sur D, Dutta S, Sarkar BL, Manna B, Bhattacharya MK, Datta KK, et al. Occurrence, significance and molecular epidemiology of cholera outbreaks in West Bengal. Indian J Med Res 2007;125:772-776
34. Mosley WH, Woodward WE, Aziz KM, Rahman AS, Chowdhury AK, Ahmed A, et al. The 1968-1969 cholera-vaccine field trial in rural East Pakistan. Effectiveness of monovalent Ogawa and Inaba vaccines and a purified Inaba antigen, with comparative results of serological and animal protection tests. J Infect Dis 1970;(Suppl 121):1-9.
35. Faruque AS, Malek MA, Khan AI, Huq S, Salam MA, Sack DA. Diarrhoea in elderly people: aetiology, and clinical characteristics. Scand J Infect Dis 2004;36:204-208
36. Khan WA, Saha D, Rahman A, Salam MA, Bogaerts J, Bennish ML. Comparison of single-dose azithromycin and 12-dose, 3-day erythromycin for childhood cholera: a randomised, double-blind trial. Lancet 2002;360:1722-1727
37. Cash RA, Music SI, Libonati JP, Craig JP, Pierce NF, Hornick RB. Response of man to infection with Vibrio cholerae. II. Protection from illness afforded by previous disease and vaccine. J Infect Dis 1974;130:325-333
38. Levine MM, Black RE, Clements ML, Cisneros L, Nalin DR, Young CR. Duration of infection-derived immunity to cholera. J Infect Dis 1981;143:818-820
39. Clemens JD, Sack DA, Harris JR, Van Loon F, Chakraborty J, Ahmed F, et al. Field trial of oral cholera vaccines in Bangladesh: results from three-year follow-up. Lancet 1990; 335:270-273
40. Tacket CO, Cohen MB, Wasserman SS, Losonsky G, Livio S, Kotloff K, et al. Randomized, double-blind, placebocontrolled, multicentered trial of the efficacy of a single dose of live oral cholera vaccine CVD 103-HgR in preventing cholera following challenge with Vibrio cholerae O1 El Tor Inaba three months after vaccination. Infect Immun 1999; 67:6341-6345
41. Taylor DN, Tacket CO, Losonsky G, Castro O, Gutierrez J, Meza R, et al. Evaluation of a bivalent (CVD 103-HgR/CVD 111) live oral cholera vaccine in adult volunteers from the United States and Peru. Infect Immun 1997;65:3852-3856
42. Qadri F, Chowdhury MI, Faruque SM, Salam MA, Ahmed T, Begum YA, et al. Peru-15, a live attenuated oral cholera vaccine, is safe and immunogenic in Bangladeshi toddlers and infants. Vaccine 2007;25:231-238
43. Wade WF. B-cell responses to lipopolysaccharide epitopes: who sees what first - does it matter? Am J Reprod Immunol 2006;56:329-336
44. Meeks MD, Saksena R, Ma X, Wade TK, Taylor RK, Kovac P, et al. Synthetic fragments of Vibrio cholerae O1 Inaba O-specific polysaccharide bound to a protein carrier are immunogenic in mice but do not induce protective antibodies. Infect Immun 2004;72:4090-4101
45. Nelson EJ, Chowdhury A, Harris JB, Begum YA, Chowdhury F, Khan AI, et al. Complexity of rice-water stool from patients with Vibrio cholerae plays a role in the transmission of infectious diarrhea. Proc Natl Acad Sci U S A 2007;104:19091-19096
46. Harris JB, Larocque RC, Chowdhury F, Khan AI, Logvinenko T, Faruque AS, et al. Susceptibility to Vibrio cholerae infection in a cohort of household contacts of patients with cholera in Bangladesh. PLoS Negl Trop Dis 2008;2:e221.